Background: Central pontine myelinolysis (CPM)/extrapontine myelinolysis (EPM) is one of the most serious neurological complications that can occur after orthotopic liver transplantation (OLT). We analyzed the risk factors for CPM/EPM in OLT patients. Methods: We retrospectively reviewed the records of 1,247 patients who underwent OLT between 1992 and 2005. We compared demographic, clinical and biological parameters of patients with CPM/EPM with those of age-, sex- and operation date-matched patients without CPM/EPM (controls). Results: Of 1,247 patients, 11 (0.88%) were diagnosed with CPM/EPM based on neuroimaging findings. A higher Model for End-Stage Liver Disease-Na score, preoperative hyponatremia and hypocholesterolemia, as well as greater changes in electrolytes, especially sodium, during surgery, were observed in the CPM/EPM group (p < 0.05). Conclusion: CPM/EPM after OLT is more likely to occur in patients with more severe preoperative liver dysfunction and greater changes in electrolyte imbalance, especially sodium, during surgery.

Keywords:
Central pontine myelinolysis, Hypocholesterolemia, Hyponatremia, Model for End-Stage Liver Disease-Na score, Liver transplantation
1.
Boon AP, Carey MP, Adams DH, Buckels J, McMaster P: Central pontine myelinolysis in liver transplantation. J Clin Pathol 1991;44:909–914.
2.
Estol CJ, Faris AA, Martinez AJ, Ahdab-Barmada M: Central pontine myelinolysis after liver transplantation. Neurology 1989;39:493–498.
3.
Ghidoni P, Di Bella C, Masini T, Paone G, Matturri L: Central pontine and extrapontine myelinolysis after orthotopic liver transplantation. Transplant Proc 1994;26:3602–3603.
4.
Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM: Central nervous system complications in liver transplant recipients – incidence, timing, and long-term follow-up. Clin Transplant 2000;14:1–7.
5.
Yu J, Zheng SS, Liang TB, Shen Y, Wang WL, Ke QH: Possible causes of central pontine myelinolysis after liver transplantation. World J Gastroenterol 2004;10:2540–2543.
6.
Kim BS, Lee SG, Hwang S, Park KM, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Kim DS, Moon KM, Jung DH: Neurologic complications in adult living donor liver transplant recipients. Clin Transplant 2007;21:544–547.
7.
Wszolek ZK, McComb RD, Pfeiffer RF, Steg RE, Wood RP, Shaw BW Jr, Markin RS: Pontine and extrapontine myelinolysis following liver transplantation. Relationship to serum sodium. Transplantation 1989;48:1006–1012.
8.
Shintani M, Yamashita M, Nakano A, Aotani D, Maeda K, Yamamoto T, Nishimura H: Central pontine and extrapontine myelinolysis associated with type 2 diabetic patient with hypokalemia. Diabetes Res Clin Pract 2005;68:75–80.
9.
Sugimoto T, Murata T, Omori M, Wada Y: Central pontine myelinolysis associated with hypokalaemia in anorexia nervosa. J Neurol Neurosurg Psychiatry 2003;74:353–355.
10.
Riggs JE, Schochet SS Jr: Osmotic stress, osmotic myelinolysis, and oligodendrocyte topography. Arch Pathol Lab Med 1989;113:1386–1388.
11.
Falcone N, Compagnoni A, Meschini C, Perrone C, Nappo A: Central pontine myelinolysis induced by hypophosphatemia following Wernicke’s encephalopathy. Neurol Sci 2004;24:407–410.
12.
Michell AW, Burn DJ, Reading PJ: Central pontine myelinolysis temporally related to hypophosphataemia. J Neurol Neurosurg Psychiatry 2003;74:820.
13.
Riggs JE, Hogg JP: Central pontine myelinolysis: association with parenteral magnesium administration. Mil Med 2000;165:494–495.
14.
Singh N, Yu VL, Gayowski T: Central nervous system lesions in adult liver transplant recipients: clinical review with implications for management. Medicine (Baltimore) 1994;73:110–118.
15.
Kabeer MH, Filo RS, Milgrom ML, Pescovitz MD, Leapman SB, Lumeng L, Jindal RM: Central pontine myelinolysis following orthotopic liver transplant: association with cyclosporine toxicity. Postgrad Med J 1995;71:239–241.
16.
Fryer JP, Fortier MV, Metrakos P, Verran DJ, Asfar SK, Pelz DM, Wall WJ, Grant DR, Ghent CN: Central pontine myelinolysis and cyclosporine neurotoxicity following liver transplantation. Transplantation 1996;61:658–661.
17.
Beltran J, Taura P, Garcia-Valdecasas JC, Navasa M, Zavala E, Anglada T, Soley R, Alvarez L, Visa J: Neurological disorders and intraoperative factors in liver transplantation. Transplant Proc 1993;25:1749–1750.
18.
Abbasoglu O, Goldstein RM, Vodapally MS, Jennings LW, Levy MF, Husberg BS, Klintmalm GB: Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin Transplant 1998;12:263–269.
19.
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91–96.
20.
Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G: Evidence-based incorporation of serum sodium concentration into meld. Gastroenterology 2006;130:1652–1660.
21.
Wong VW, Chim AM, Wong GL, Sung JJ, Chan HL: Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl 2007;13:1228–1235.
22.
Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR: A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–470.
23.
Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD: The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 2008;40:882–889.
24.
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, Edwards E, Therneau TM: Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018–1026.
25.
Kumar S, Fowler M, Gonzalez-Toledo E, Jaffe SL: Central pontine myelinolysis, an update. Neurol Res 2006;28:360–366.
26.
Cramer SC, Stegbauer KC, Schneider A, Mukai J, Maravilla KR: Decreased diffusion in central pontine myelinolysis. AJNR Am J Neuroradiol 2001;22:1476–1479.
27.
Chu K, Kang DW, Ko SB, Kim M: Diffusion-weighted MR findings of central pontine and extrapontine myelinolysis. Acta Neurol Scand 2001;104:385–388.
28.
Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L: Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157:792–796.
29.
D’Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G: Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 1998;33:1213–1218.
30.
Bramhall SR, Minford E, Gunson B, Buckels JA: Liver transplantation in the UK. World J Gastroenterol 2001;7:602–611.
31.
Lui CC, Chen CL, Chang YF, Lee TY, Chuang YC, Hsu SP: Subclinical central pontine myelinolysis after liver transplantation. Transplant Proc 2000;32:2215–2216.
32.
Kato T, Hattori H, Nagato M, Kiuchi T, Uemoto S, Nakahata T, Tanaka K: Subclinical central pontine myelinolysis following liver transplantation. Brain Dev 2002;24:179–182.
33.
Laureno R, Karp BI: Myelinolysis after correction of hyponatremia. Ann Intern Med 1997;126:57–62.
34.
Lampl C, Yazdi K: Central pontine myelinolysis. Eur Neurol 2002;47:3–10.
35.
Rodriguez J, Benito-Leon J, Molina JA, Ramos A, Bermejo F: Central pontine myelinolysis associated with cyclosporin in liver transplantation. Neurologia 1998;13:437–440.
36.
Bird GL, Meadows J, Goka J, Polson R, Williams R: Cyclosporin-associated akinetic mutism and extrapyramidal syndrome after liver transplantation. J Neurol Neurosurg Psychiatry 1990;53:1068–1071.
37.
Burkhalter EL, Starzl TE, Van Thiel DH: Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. J Hepatol 1994;21:572–577.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.